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burden of cost on society (p  0.001). The largest portion of direct cost was devoted 
to medicines (46%) followed by laboratory investigations (32%). Comparing cost 
with family income, we also found that poorest segment of society is spending about 
18% of total family income on diabetes care. CONCLUSIONS: The overwhelming
cost threatens to stunt economic growth and undermines the living standard. The 
overall cost can be abridged by prevention of diabetes, earlier detection of disease and 
improved diabetes care. Prevention programs need to be initiated at lager scale to
enhance health gain to the individual and to reverse the advance of this epidemic. 
Policy makers need to ascertain the priority of diabetes education and prevention 
programs at primary health care outlets as an integral component.
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OBJECTIVES: This retrospective matched cohort study compared resource utilization
and costs between diabetic and non-diabetic patients requiring skilled nursing facility
(SNF) admissions. METHODS: Patients with a SNF admission for at least 30 days 
during 2004 were identiﬁ ed from a 5% random sample of Medicare patients. The 
“diabetes” cohort consisted of patient with an ICD-9-CM diagnosis on 1 SNF claims. 
Each diabetes patient was matched (by age, sex, and race) with one patient having no
diabetes claims in 2004 and followed for 12 months. The diabetes and non-diabetes
cohorts were compared, both overall and within subgroups deﬁ ned by age, with 
respect to rates of diabetes complications/conditions and co-morbid conditions, health
care resource utilization, and Medicare payments in 2005. Ordinary least squares 
regression was used to estimate adjusted costs controlling for comorbid conditions
(i.e., selected chronic conditions, Charlson comorbidity score). RESULTS: We identi-
ﬁ ed 20,477 diabetic patients and 78,154 non-diabetic patients in 2004. Following
matching, there were 20,158 in each group (45% aged 80 years, 62% female, 82%
white). Relative to matched controls, diabetic patients had higher Charlson comorbid-
ity scores and were more likely to have complications such as congestive heart failure 
(24.1% vs. 18.1%, p  0.01) and renal disease (11.2% vs. 6.7%, p  0.01). On
average, diabetic patients had an additional one-half day (p  0.01) in the hospital 
over one year of follow-up. Total unadjusted mean Medicare payments were greater 
among diabetic patients than controls ($26,075 vs. $24,622, p  0.01), primarily due
to differences in inpatient costs. After adjusting for comorbidities, total costs were 
$969 higher among diabetic patients (p  0.01). Excess costs were greater among 
patients 70 years ($1269, p  0.01) versus those 70 years ($892, p  0.01). CON-
CLUSIONS: These ﬁ ndings suggest that diabetic patients in skilled nursing facilities
had higher health care costs than non-diabetic patients even after controlling for
complications related to diabetes and chronic comorbidity.
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OBJECTIVES: Morbidity, mortality, and costs of Type 2 Diabetes (T2D) remain high 
despite the available efﬁ cacious treatment options. New agents have shown improve-
ments in A1C and other surrogates but long-term impacts are unknown. METHODS:
Data from randomized controlled trial of liraglutide monotherapy (LEAD 3) was used 
to determine long-term consequences of treatment with liraglutide, a new OD GLP-1 
analog, compared to glimepiride in a simulated 30-year follow-up. The CORE diabetes 
model, calibrated to LEAD 3 baseline patient characteristics, employed data from 
long-term studies to project morbidity, mortality and costs of T2D. We simulated
clinical and economic consequences of patients receiving liraglutide 1.2mg and 1.8mg
compared to glimepiride 8 mg, all as monotherapy, for treatment of T2D. The effect
of treatment on A1C, SBP, lipids, weight and risk of hypoglycemia was taken into
account. Survival, cumulative incidence of CV, ocular, renal events and costs (dis-
counted 3%/yr) were estimated over three periods: 10, 20, 30 years. RESULTS: Simu-
lations produced higher survival rates for liraglutide 1.8 mg and 1.2 mg compared to
glimepiride after 30 years’ follow-up (16.5%, 13.6%, 7.3%, respectively). Highest
difference in fatal events across treatment groups related to end-stage renal disease, 
although the main cause of death in all groups was associated with CV events. Non-
fatal renal and ocular events were lower for both liraglutide doses. Neuropathies that
led to a ﬁ rst or recurrent amputation were higher for glimepiride compared to the 
liraglutide doses. The average cumulative cost per patient was US$9367 higher for
glimepiride at year 30, compared to liraglutide 1.8mg, and US$6491 higher than 
liraglutide 1.2 mg. CONCLUSIONS: The main cost component for all groups was
management of CV events. Using the CORE model and data from LEAD 3, projected
survival, diabetes complications and costs over the long term favored liraglutide 
1.2 mg and 1.8 mg compared to glimepiride in the treatment of T2D.
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OBJECTIVES: Poor control of type 2 diabetes (T2D) results in substantial morbidity
and economic burden to the health care system. Studies of new T2D treatments are
rarely designed to assess mortality, complication rates and costs. We sought to estimate 
long-term consequences of liraglutide and rosiglitazone both as add-on to glimepiride. 
METHODS: To estimate clinical and economic consequences, we used the CORE 
diabetes model, a validated cohort model that uses data from long-term clinical trials
to simulate morbidity, mortality and costs of T2D. Clinical data were extracted from 
the randomized double-blinded placebo-controlled LEAD 1 trial evaluating two doses 
(1.2 mg and 1.8 mg) of a once daily human GLP-1 analog liraglutide, or rosiglitazone
4 mg, added to glimepiride. The CORE diabetes model was calibrated to the LEAD 1
baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular 
and renal events and costs were estimated over three periods: 10, 20 and 30 years.
RESULTS: In a cohort of 5000 patients per treatment followed for 30 years, liraglutide 
1. mg and 1.8 mg had higher survival compared to the group treated with rosiglitazone 
(15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and
ocular events. Cardiovascular deaths after 30 years were 69.7%, 68.4% and 72.5%,
for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent 
amputations were lower in the rosiglitazone group compared to both doses of liraglu-
tide (number of events: 565, 529 and 507 for liraglutide 1.2 mg, 1.8 mg, and rosigli-
tazone, respectively). CONCLUSIONS: Overall cumulative costs per patient were 
lower in both liraglutide groups compared to rosiglitazone mainly driven by the costs
of cardiovascular events (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 
1.8 mg, and rosiglitazone, respectively). Projected survival and long term outcomes 
favored liraglutide 1.2 mg and 1.8 mg over rosiglitazone both added to glimepiride.
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OBJECTIVES: Among patients diagnosed with diabetic peripheral neuropathic pain 
(DPNP); whether adherence to duloxetine therapy was correlated with opioid medica-
tion use and health care expenditures. METHODS: Diabetic patients who were dis-
pensed duloxetine between March 1, 2005 and December 31, 2005 were identiﬁ ed 
from a large administrative claims database and an “index date” was assigned based
on the dispense date of the ﬁ rst duloxetine claim. Included patients were 18 to 64 
years old, diagnosed with DPNP in the one year prior to the index date, and received 
opioids in the prior 90 days. Adherence to duloxetine therapy was based on medica-
tion possession ratio (MPR), and patients were dichotomized as “continuous” (MPR
q 0.8) and “non-continuous” (MPR  0.8) users. We examined changes in short-acting 
(SA) and long-acting (LA) opioid utilization one year before and after the index date. 
One year health care utilization and costs were also examined. Multivariate linear 
regressions were performed to examine the association between duloxetine adherence 
and study outcomes, controlling for baseline demographic and clinical characteristics.
RESULTS: We identiﬁ ed 97 continuous users and 245 non-continuous users of dulox-
etine. Compared with non-continuous patients, continuous users had a greater reduc-
tion in days on SA hydrocodone (30.2, p  0.05), number of SA hydrocodone 
prescriptions (1.7, p  0.05), and days on DPNP-related SA opioids (23.8, p  0.05). 
We did not observe any signiﬁ cant reduction in LA opioid use. Continuous users also
had 40% fewer inpatient stays (p  0.05) and fewer days in hospital (3.5, p  0.05). 
In the regression model, we found continuous users had $17,062 less (p  0.05) total 
health care cost than non-continuous users mainly attributable to lower inpatient costs 
($16,932, p  0.05). The outpatient and pharmacy costs were similar between cohorts.
CONCLUSIONS: Continuous duloxetine users were more likely to have a reduction
in SA opioids use and have lower hospital expenditures than non-continuous dulox-
etine users.
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OBJECTIVES: study compared the daily average consumption (DACON) of insulin 
detemir (DET), insulin glargine (GLAR) and NPH insulin in patients with T2D in a
real-world setting. METHODS: Patients with T2D (per ICD-9 code 250.x1 250.x3)
newly treated with DET, GLAR or NPH insulin monotherapy were identiﬁ ed in the 
Verispan Electronic Data Warehouse (SDI, Plymouth Meeting, PA) from 7/1/2006 to 
6/31/2007. A study limitation is that Verispan data has an open architecture and does
not include eligibility data, but ﬁ ltering techniques were employed to eliminate cohort 
shrinkage. A patient level DACON was calculated as the number of insulin units dis-
pensed from the ﬁ rst to the second to last prescription in the observation period 
divided by the elapsed days from the ﬁ rst to last ﬁ ll. Unpaired t-tests and chi-square 
